News | April 28, 2023
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Bourgoin early development hub broadens offerings for oral solid dose formulations
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Acetazolamide is used to treat glaucoma
Subscribe To Our Newsletter & Stay Updated
